Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADL-018 vs Xolair PK/PD study in healthy adults
NCT05564611Phase 1Completed
- Sponsor
- Kashiv BioSciences
- Start
- Nov 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adl018 in chronic spontaneous urticaria (CSU) and asthma (2 arms), sponsored by Kashiv BioSciences. Primary endpoints: Maximum Serum Concentration, Area Under the Curve from time zero to last measurable concentration and 2 more. Started Nov 2022; status: completed.
02
Drugs
adl018
03
Conditions
chronic spontaneous urticaria (CSU)asthma
Beyond the preview
Go deeper on NCT05564611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564611.